The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis

NCT02765399 on ClinicalTrials.gov · last registry update 2022-04-12

A small phase 4 — 23 participants, against a typical 75. The sponsor logged completion for 28 February 2019. Primary outcome, as filed: Change in Liver Fat Content. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Helsinki University Central Hospital
Sponsor type: Other
Enrollment: 23
Started: 2015-02-01
Primary completion: 2019-02-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Liver Fat Content

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.